12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Forodesine: Phase II data

Top-line data from an open-label, international Phase II trial in 101 patients with stage IIB-IVA CTCL who had received >=3 prior systemic therapies showed that once-daily 200 mg oral forodesine produced an ORR of 11%, with 11 partial responses, plus 56 cases of stable disease. BioCryst said the sample size was too small...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >